Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
about
Minimal residual disease and circulating tumor cells in breast cancerCirculating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer researchApplication of optically-induced-dielectrophoresis in microfluidic system for purification of circulating tumour cells for gene expression analysis- Cancer cell line modelSingle Cell Isolation and Analysis'Omic approaches to preventing or managing metastatic breast cancerMicrofluidic, label-free enrichment of prostate cancer cells in blood based on acoustophoresis.Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies.Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.Towards Engineered Processes for Sequencing-Based Analysis of Single Circulating Tumor CellsCirculating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancerSingle cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.Engineering self-contained DNA circuit for proximity recognition and localized signal amplification of target biomoleculesIsolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancerAccurate detection of carcinoma cells by use of a cell microarray chipNanotechnology for the detection and kill of circulating tumor cells.Microfluidic, marker-free isolation of circulating tumor cells from blood samplesDetection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies.CTC enumeration and characterization: moving toward personalized medicine.Stabilization of circulating tumor cells in blood using a collection device with a preservative reagent.Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin.A novel platform for detection of CK+ and CK- CTCs.Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancerClinical relevance and biology of circulating tumor cells.Development of individualized anti-metastasis strategies by engineering nanomedicinesThe isolation and characterization of CTC subsets related to breast cancer dormancyAn anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.Continual collection and re-separation of circulating tumor cells from blood using multi-stage multi-orifice flow fractionationThe potential for liquid biopsies in the precision medical treatment of breast cancer.Detecting circulating tumor cells: current challenges and new trends.Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.Circulating tumor cell enrichment based on physical properties.The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer.MUC1 and metastatic cancer: expression, function and therapeutic targeting.Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy.Circulating tumor cells as emerging tumor biomarkers in breast cancer.Isolated, disseminated and circulating tumour cells in prostate cancer.Enrichment, detection and clinical significance of circulating tumor cells.Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes.
P2860
Q27010152-5B426B39-4807-453E-A7BA-0C726B2618DBQ27024191-01A6E9C2-C24A-4D77-8AD8-3175C569A54EQ27349679-3C88F768-0354-45AC-83E8-802E7AD79B95Q28078083-31397B91-E1F0-4332-A500-3F7F5D17198CQ28730572-DF2B8D96-5188-452D-8C6C-2431A9505F9DQ30449185-5413A9E9-5B91-44BD-9E80-48CE2D5AB7A1Q30581258-9877F259-C080-4181-9C30-1821536218A3Q31006508-F9E7FAED-D0E9-4F83-9611-113ED974BE4FQ33604017-A8F9AC4B-63A9-4F0F-8F91-7754300BC2A1Q33630812-4AB10371-8D4C-4117-8183-D15654D3653AQ33806957-6A03AB7E-5FC9-4DF5-A136-5B612E382F53Q34044502-0E32B88F-3B1D-4F0A-87DD-F2645FA84E54Q34090338-55D251B2-5990-4A97-90A1-30FEBF52564EQ34161251-2FF0B409-AFD5-479B-AEBE-DBDDBFE91D9EQ34187178-FFB6BBDC-E75B-47DD-94CC-C03D6F6C5F7BQ34241179-0FA3AE1B-7AD3-4C93-8F15-F61047585D93Q34263808-43528D76-2330-4686-890F-43493FD58342Q34286198-DDB47711-E3BC-4907-AFD6-5B4D254DFA33Q34577724-E1528E12-52F9-465D-9179-370B4F392FBCQ35112470-D9690314-EA4F-431A-A84D-EE9262954834Q35157131-7805443F-EE36-4923-9ADF-9B39FF7E89A9Q35612329-18F04405-8091-45CF-9954-0E29DBE43152Q35784738-F8BD1A8F-4462-4F12-B849-98F59313BB84Q35828584-BD49F5A2-224F-494C-9946-2A05891B2161Q35889548-B71501CC-57CC-46A5-9FFD-7E94E4F8DAECQ35967474-AE998201-6768-4A6C-9364-6ECEC321D697Q36343283-05608B49-B311-4D6E-AD8B-3362A1E087C7Q36413078-D7C80285-4593-4706-A814-715D6E1AE4B9Q36597417-8AC19478-0118-4215-B269-3EF82231AC71Q36849660-34333442-CEBD-4CA6-8387-8EAD02D430A7Q36915318-B6E9B96F-0351-40CA-B0CA-6BA4D4338CC8Q37140168-7850C69E-1E76-436D-BE88-E2A133890390Q37315616-7C132B3B-BA39-47A7-A4C3-617673F3466FQ37520184-3A6F5180-FA9F-4585-887E-0F6F9C53CD32Q37636939-5850ED8C-009D-4C5B-A182-1E5D166D2D50Q37898107-5FCBA82B-AEC8-4229-BE01-24670479FB07Q37908134-04FFDDBA-EC0B-4B89-9A47-40EAB859D8BEQ38024987-A15688A1-CDC0-4B52-9152-17E84CC685D9Q38102590-3E9ACCAA-1653-41A9-ADB9-029B3027171EQ38123962-762D79D6-3C05-4B1A-A4F4-DE4F1F55C337
P2860
Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Enrichment with anti-cytokerat ...... static breast cancer patients.
@en
type
label
Enrichment with anti-cytokerat ...... static breast cancer patients.
@en
prefLabel
Enrichment with anti-cytokerat ...... static breast cancer patients.
@en
P2093
P2860
P356
P1476
Enrichment with anti-cytokerat ...... static breast cancer patients.
@en
P2093
David Burgess
David Krag
Edward Manna
Glenn Deng
Julian F Burke
Michael Herrler
P2860
P2888
P356
10.1186/BCR2131
P577
2008-08-07T00:00:00Z
P5875
P6179
1004596195